Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.

CPE-005 · Fibrosis risk

LV-FIB-01: FIB-4 and its stratum

FIB-4 and its stratum. Evaluates age, AST, ALT and platelets available.

Active rulePriority 4Liver engine v1.0.0

Condition

  • age, AST, ALT and platelets available

What it reports

  • FIB-4 = age × AST ÷ (platelets × √ALT)
  • Low risk: below 1.3 (below 2.0 from age 65)
  • Indeterminate: 1.3 to 2.67 (2.0 to 2.67 from age 65)
  • High risk: above 2.67

Diagnostic boundary

  • A rule-out test for advanced fibrosis, not a diagnosis of fibrosis.

Evidence

  • EV-AASLD-2023Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.Supports: FIB-4 first for risk stratification; thresholds <1.3 and >2.67; elastography 8 and 12 kPa; ELF 7.7 and 9.8 ALT upper limits near 29–33 U/L (men) and 19–25 U/L (women) Cardiovascular risk is the leading cause of death in MASLD
  • EV-MCPHERSON-2017McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740-751.Supports: FIB-4 lower cutoff of 2.0 in patients aged 65 and over

Cases where this rule fires

Open a case to see this rule fire with real inputs, then change the values until it stops.

The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.

Contact Biod